Physician profile
Rupal Doshi Clair
NPI 1811204332
$5,281.96
in general payments reported to CMS, 2019-2025
21 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $117 · 2021: $171 · 2022: $223 · 2023: $2,430 · 2024: $816 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,292 · Food and Beverage: $2,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,291.51 |
| Food and Beverage | $2,190.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $2,152.94 | 2023 | Visumax |
| Alcon Vision LLC | $1,115.19 | 2019-2025 | Precision7, Precision 7, Total30 |
| Bausch & Lomb Americas INC. | $562.25 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Astellas Pharma US INC | $257.54 | 2024-2025 | Izervay |
| Johnson & Johnson Vision Care, INC. | $183.95 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $181.98 | 2019-2021 | |
| Dompe US, INC. | $122.93 | 2025 | Oxervate |
| Rxsight INC | $93.05 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Carl Zeiss Meditec, INC. | $79.74 | 2019-2020 | |
| Glaukos Corporation | $76.36 | 2019-2020 | |
| Coopervision INC. | $76.12 | 2019-2025 | Misight Contact Lens, Biofinity Contact Lens, Onefit Contact Lens |
| Abbvie INC. | $61.58 | 2023 | Lumigan |
| Tearlab Corp | $60.33 | 2023 | Tearlab Osmolarity System |
| Shire North American Group INC | $47.93 | 2019 | |
| Aerie Pharmaceuticals, INC. | $46.28 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45.30 | 2021-2022 | |
| Oyster Point Pharma, INC. | $33.65 | 2022 | |
| Allergan, INC. | $27.37 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $22.81 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $19.63 | 2022 | |
| Genentech USA, INC. | $15.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupal Clair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.